A qualitative exploration of the experiences of adults with cystic fibrosis unable to benefit from triple combination therapy.

Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a highly effective modulator therapy that has transformed the lives of many people with Cystic Fibrosis (CF). However, limited research has explored the experiences of those not able to benefit from ETI due t…

Preview only. Read the full abstract at the source